Acumen Pharmaceuticals Statistics
Share Statistics
Acumen Pharmaceuticals has 60.57M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 60.57M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 70.73% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 264 |
| FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 1.75M, so 2.89% of the outstanding
shares have been sold short.
| Short Interest | 1.75M |
| Short % of Shares Out | 2.89% |
| Short % of Float | 3.89% |
| Short Ratio (days to cover) | 6.36 |
Valuation Ratios
The PE ratio is -1.01 and the forward
PE ratio is -0.64.
Acumen Pharmaceuticals's PEG ratio is
-0.02.
| PE Ratio | -1.01 |
| Forward PE | -0.64 |
| PS Ratio | 0 |
| Forward PS | 1.1 |
| PB Ratio | 0.57 |
| P/FCF Ratio | -1.2 |
| PEG Ratio | -0.02 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Acumen Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.46,
with a Debt / Equity ratio of 0.16.
| Current Ratio | 6.46 |
| Quick Ratio | 6.46 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | -0.3 |
| Debt / FCF | -0.34 |
| Interest Coverage | -28.03 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,677,524.59 |
| Employee Count | 61 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -71.82% in the
last 52 weeks. The beta is 0.09, so Acumen Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.09 |
| 52-Week Price Change | -71.82% |
| 50-Day Moving Average | 1.11 |
| 200-Day Moving Average | 1.97 |
| Relative Strength Index (RSI) | 49.08 |
| Average Volume (20 Days) | 224,361 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -114.02M |
| Net Income | -102.33M |
| EBITDA | -98.08M |
| EBIT | -98.26M |
| Earnings Per Share (EPS) | -1.71 |
Full Income StatementBalance Sheet
The company has 35.63M in cash and 29.7M in
debt, giving a net cash position of 5.92M.
| Cash & Cash Equivalents | 35.63M |
| Total Debt | 29.7M |
| Net Cash | 5.92M |
| Retained Earnings | -325.13M |
| Total Assets | 238.99M |
| Working Capital | 150.7M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -86.22M
and capital expenditures -16K, giving a free cash flow of -86.23M.
| Operating Cash Flow | -86.22M |
| Capital Expenditures | -16K |
| Free Cash Flow | -86.23M |
| FCF Per Share | -1.44 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
